Medicare GLP-1 Bridge (CMS) coverage for Wegovy (Weight Loss)

What you need to qualify

• Age 18 and older
• BMI of 35 or higher
• BMI of 27 or higher with a weight-related condition (pre-diabetes, previous MI, previous stroke, symptomatic PAD, heart failure with preserved ejection fraction, uncontrolled hypertension, and CKD stage 3a or above)
• Diagnosis documented with a code (E66)
• Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Prescriber attestation (under penalty of perjury) that information provided is true and correct
• Obesity diagnosis code (E66 family) on the prescription
• Documentation that patient is >= 18 years of age
• Documentation that the GLP-1 is prescribed to reduce excess body weight and maintain weight reduction only (not for any other approved indication)
• Documentation that patient has not previously received a GLP-1 through their Medicare Part D plan
• Documentation that patient does NOT have type 2 diabetes, moderate-to-severe sleep apnea, or MASH
• Documentation of qualifying BMI (>= 35, or >= 30 with HFpEF/uncontrolled HTN/CKD stage 3a+, or >= 27 with pre-diabetes/prior MI/prior stroke/symptomatic PAD)
• Documentation of qualifying comorbidity if BMI < 35

Quantity limits

• all covered strengths — 28-day or 30-day fills only

Approval and renewal

• To renew, the plan looks for Subsequent fills do not require a new prior authorization unless the patient switches from one covered GLP-1 drug to a different one.

Not covered when

• Patients who have previously received a GLP-1 through their Medicare Part D plan are not eligible
• Patients with type 2 diabetes must submit to their Part D plan (not eligible for Bridge)
• Patients with moderate-to-severe sleep apnea must submit to their Part D plan (not eligible for Bridge)
• Patients with MASH must submit to their Part D plan (not eligible for Bridge)
• Patients enrolled in private fee-for-service plans, section 1876 cost contract plans, section 1833 healthcare prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans are not eligible unless also enrolled in a standalone PDP
• Prescription indicated for any approved indication other than weight reduction and maintenance of weight reduction is not eligible

Policy note: This is a short-term CMS demonstration program operating outside of Medicare Part D plan coverage, launching July 1, 2026. The program uses a central processor for PA, claims processing, and pharmacy payment. PA request is pharmacy-initiated (sent to prescriber within 24-72 hours after claim submission). Only 28-day or 30-day fills are covered. A new PA is required only if a patient switches from one covered GLP-1 to another. The program independently verifies patient information (e.g., checks Medicare data for T2DM). Prescriber must not be on the CMS Preclusion List. Wegovy injection and tablets are covered; oral semaglutide (Rybelsus) is not listed as covered. Only Wegovy, Foundayo (oral semaglutide tablets), and Zepbound KwikPen are covered — single-dose Zepbound pen and Zepbound vials are NOT covered.

Policy effective July 1, 2026 · verified July 8, 2026 · source: medicare-glp1-bridge-prescriber-guide.pdf